From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Rocatinlimab (AMG 451) (KHK4083) is a fully humanimmunoglobulinG1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .
Ramucirumab (anti-VEGFR) is a humanVEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant humanimmunoglobulinG1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
Tozorakimab (MEDI-3506) is a humanimmunoglobulinG1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
Maridebart (AMG133 antibody) is a humanimmunoglobulinG1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .
Nesvacumab is a fully humanimmunoglobulinG1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches .
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of humanimmunoglobulinG2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulinG4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two humanG-CSF fused to a humanimmunoglobulinG2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
DIDNTB is a dye. DIDNTB exhibits chemical sensitivity and specificity toward albumin. DIDNTB is much less affected by other proteins. DIDNTB enables the detection of urinary albumin at concentrations ≥10 mg/L .\n
Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) humanimmunoglobulinG1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity. Belrestotug can be used for cancer and immunological research such as colon cancer .
Firsekibart is an immunoglobulinG4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
Calpurbatug is an immunoglobulinG1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
Tosatoxumab (AR-301; KBSA301) is a humanimmunoglobulinG1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
Efpixileukin alfa is a fusion protein that combines human IL-2 variant fused at the C-terminus to humanimmunoglobulinG1 (IgG1) Fc fragment. Efpixileukin alfa is an immunomodulator .
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulinG4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
Nelvutamig is a humanized immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) antibody targeting ENPP3/CD203c and CD3E. The corresponding isotype control is: Humanimmunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) .
hIgG–hFc receptor-IN-1 (comp 66) is a humanimmunoglobulinG–human neonatal Fc receptor (hIgG–hFcRn) protein-protein interaction inhibitor, with an IC50 of 2 μM .
Enzelkitug is a humanized immunoglobulinG1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
Elegrobart is an immunoglobulinG1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
SIM-0235 is humanized immunoglobulinG1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
Rinvatercept, a fusion protein, is a glycyl (1)-chimeric N-terminal (1-108)-peptide (2-109) combined from the sequences of the extracellular domains of the human ACVR2A/B, and is fused via a G3 peptide linker (110-112) to an immunoglobulinG1 (IgG1) Fc fragment. Rinvatercept can be used for research of neuromuscular disease .
Sovipostobart is an immunoglobulinG1-kappa, anti-CTLA-4human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
Futermestotug is a humanized immunoglobulinG1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
Oturkibart is a humanized immunoglobulinG4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
Exerenibart is an immunoglobulinG4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of humanimmunoglobulinG4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of humanimmunoglobulinG4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
Ricefidase (KJ-103) is a recombinant humanimmunoglobulinG-degrading enzyme. Ricefidase efficiently cleaves humanIgG at the hinge region. Ricefidase rapidly reduces IgG levels. Ricefidase has low immunogenicity and clears AAV neutralizing antibodies. Ricefidase is applicable to research related to desensitization of all IgG subclasses and improvement of the suitability of AAV-based gene therapy .
Afivastobart (AB598) is a humanENTPD1 (CD39)-targeting monoclonal antibody with antineoplastic activity.Afivastobart binds as a monoclonal antibody to modulate Homo sapiensENTPD1 activity.Afivastobart constitutes a glycoform alfa immunoglobulinG1-kappa monoclonal antibody .
Z223-2027 is a FcRn inhibitor. Z223-2027 competitively blocks the binding of immunoglobulin G (IgG) to FcRn. Z223-2027 can be used in the research of IgG-mediated autoimmune diseases .
JNJ-55920839 (CNTO-6358) is a fully humanimmunoglobulinG1κ monoclonal antibody and a selective Interferonα/ω neutralizer, with a Kd value of 0.9-10.7 pM against hIFNα and a Kd of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus .
Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia .
DIDNTB is a dye. DIDNTB exhibits chemical sensitivity and specificity toward albumin. DIDNTB is much less affected by other proteins. DIDNTB enables the detection of urinary albumin at concentrations ≥10 mg/L .\n
Rocatinlimab (AMG 451) (KHK4083) is a fully humanimmunoglobulinG1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .
Ramucirumab (anti-VEGFR) is a humanVEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant humanimmunoglobulinG1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
Tozorakimab (MEDI-3506) is a humanimmunoglobulinG1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
Maridebart (AMG133 antibody) is a humanimmunoglobulinG1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .
Nesvacumab is a fully humanimmunoglobulinG1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches .
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of humanimmunoglobulinG2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulinG4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two humanG-CSF fused to a humanimmunoglobulinG2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) humanimmunoglobulinG1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity. Belrestotug can be used for cancer and immunological research such as colon cancer .
Firsekibart is an immunoglobulinG4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
Calpurbatug is an immunoglobulinG1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulinG1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
Tosatoxumab (AR-301; KBSA301) is a humanimmunoglobulinG1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
Efpixileukin alfa is a fusion protein that combines human IL-2 variant fused at the C-terminus to humanimmunoglobulinG1 (IgG1) Fc fragment. Efpixileukin alfa is an immunomodulator .
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulinG4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
Nelvutamig is a humanized immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) antibody targeting ENPP3/CD203c and CD3E. The corresponding isotype control is: Humanimmunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) .
Enzelkitug is a humanized immunoglobulinG1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
Elegrobart is an immunoglobulinG1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
SIM-0235 is humanized immunoglobulinG1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
Rinvatercept, a fusion protein, is a glycyl (1)-chimeric N-terminal (1-108)-peptide (2-109) combined from the sequences of the extracellular domains of the human ACVR2A/B, and is fused via a G3 peptide linker (110-112) to an immunoglobulinG1 (IgG1) Fc fragment. Rinvatercept can be used for research of neuromuscular disease .
Sovipostobart is an immunoglobulinG1-kappa, anti-CTLA-4human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
Futermestotug is a humanized immunoglobulinG1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
Oturkibart is a humanized immunoglobulinG4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
Exerenibart is an immunoglobulinG4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of humanimmunoglobulinG4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of humanimmunoglobulinG4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
Ricefidase (KJ-103) is a recombinant humanimmunoglobulinG-degrading enzyme. Ricefidase efficiently cleaves humanIgG at the hinge region. Ricefidase rapidly reduces IgG levels. Ricefidase has low immunogenicity and clears AAV neutralizing antibodies. Ricefidase is applicable to research related to desensitization of all IgG subclasses and improvement of the suitability of AAV-based gene therapy .
Afivastobart (AB598) is a humanENTPD1 (CD39)-targeting monoclonal antibody with antineoplastic activity.Afivastobart binds as a monoclonal antibody to modulate Homo sapiensENTPD1 activity.Afivastobart constitutes a glycoform alfa immunoglobulinG1-kappa monoclonal antibody .
JNJ-55920839 (CNTO-6358) is a fully humanimmunoglobulinG1κ monoclonal antibody and a selective Interferonα/ω neutralizer, with a Kd value of 0.9-10.7 pM against hIFNα and a Kd of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus .
AMG-329 (MEDI1116) is a humanimmunoglobulinG1λ monoclonal antibody targeting FLT3L. AMG-329 selectively binds to FLT3L, blocks FLT3L-FLT3 interaction, neutralizes soluble and cell-bound humanFLT3L activity. AMG-329 reduces circulating relative proportions of plasmacytoid dendritic cells, conventional dendritic cells, and classical monocytes. AMG-329 does not induce antibody dependent cellular cytotoxicity. AMG-329 can be used for the research of sjögren’s disease .
Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia .
The LILRA4/ILT-7/CD85g protein is a coreceptor that critically limits the innate immune response during viral infection through FCER1G signaling.It negatively regulates TLR7 and TLR9 signaling and reduces IFNA1, IFNA2, IFNA4, IFNB1, and TNF production in dendritic cells exposed to influenza virus or CpG dinucleotides.LILRA4/ILT-7/CD85g Protein, Human (HEK293, His) is the recombinant human-derived LILRA4/ILT-7/CD85g protein, expressed by HEK293 , with C-His labeled tag.
PIGR proteins play a critical role in mediating the selective transcytosis of polymerized IgA and IgM across mucosal epithelial cells, which is critical for mucosal immunity. PIGR binds these immunoglobulins at the basolateral surface, forming a complex that is transported intracellularly and secreted apically. PIGR Protein, Human (G365S, HEK293, His) is the recombinant human-derived PIGR protein, expressed by HEK293 , with C-6*His labeled tag.
ILDR2 proteins play multiple roles in cellular processes, participating in ER stress pathways, affecting lipid homeostasis, and affecting insulin secretion. It is involved in maintaining epithelial barrier function and recruiting MARVELD2/trifibrin into tight junctions, emphasizing its role in cellular integrity. ILDR2 Protein, Human (HEK293, His) is the recombinant human-derived ILDR2 protein, expressed by HEK293 , with C-6*His labeled tag.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
